CASP6 and glioblastoma: Interestingly, suppressing caspase-6 activity with its specific inhibitor concurrently protected human drug-sensitive and -resistant glioblastoma cells from enzalutamide-induced morphological shrinkage, DNA fragmentation, and apoptotic insults.